Methods

Cardiac samples
Cardiac tissue was obtained from explanted hearts of 44 patients with advanced HF who underwent a cardiac transplantation or a total artificial heart placement. Pre-transplant evaluation -including coronary artery angiography and macroscopic and histological examination of the explanted hearts -confirmed the diagnosis, aetiology and severity of the disease for all patients. Extensive individual clinical information can be found in Table S1 .
Patients were classified into three severity groups based on their clinical status at the time of transplantation. The individual clinical status was defined based on the United Network for Organ Sharing (UNOS) medical urgency status [12] and occurrence of hospitalizations for acute decompensated heart failure (ADHF) during the 3 months prior to the surgical procedure ('recent ADHF'). UNOS medical urgency status determination is based on several patient characteristics including necessity of mechanical circulatory support, inotrope IV infusion or hospitalization in an intensive care unit. Deteriorating patients were characterized by UNOS-1A status. Stable patients were defined as UNOS-2 patients with no recent ADHF. The remaining patients were classified as intermediate (UNOS-1B status or UNOS-2 status with recent ADHF). For each of the 44 explanted hearts, two spatially distinct transmural samples were obtained from non-infracted zones of both left ventricle (LV) and right ventricle (RV) immediately after cardiac explantation, leading to a total of 176 distinct tissue samples.
Microarrays
Microarray preparation and hybridization, and expression data acquisition and processing are described in the Supporting Information.
Data analysis
Unsupervised hierarchical clustering was applied to the entire data set median-centred on genes, using the Pearson correlation as a similarity metric and average linkage clustering. Results were displayed using TreeView [13] . Gene clusters were selected using 10 and 0.6 as minimal gene number and minimal correlation, respectively. GoMiner was used to identify functional categories that were over-or underrepresented in specific clusters compared to the list of all analysed genes [14] .
'Predictors' and 'molecular severity score' LV-and RV-specific data were separated into distinct data sets and analysed separately using an identical strategy:
The 'Predictor' was defined as a list of genes differentially expressed between stable and deteriorating patient groups. These genes were identified using 'significance analysis of microarrays' [15] To test whether the obtained classification was independent of the method used, we also classified stable and deteriorating samples using the prediction analysis of microarrays method [16] using a previously published strategy [10, 17] 
Hierarchical clustering and functional annotation
The 176 cardiac samples and the 4035 selected genes were clustered according to their expression profiles using a hierarchical clustering procedure (Fig. 1 
Prediction of clinical status
Effects of potential biases
The three patient groups were comparable regarding sex, age, HF aetiology and LV ejection fraction ( (Fig. S3) .
Biological reproducibility
We aimed to test whether our classification was reproducible across biological replicates. A significant correlation between MSS values obtained for the duplicate sets was observed (Fig. 4) [9, 10, 19] . In a recent study,
microarray representing genes selected for their contribution to muscular organ (patho)physiology. Replication at both the biological and the technical level, and control of experimental variations at the different steps of the study allowed detection of even subtle expression changes. We identified a set of genes of which expression changes discriminated between patients with different clinical severity levels and established that clinical deterioration of HF patients was associated with a molecular deterioration expression profile in both LV and RV. Therefore, our study confirms the potential of cardiac gene expression profiling to identify outcome predictors in patients with advanced HF.
Related findings in previous studies
It has previously been shown that gene expression profiling can discriminate between cardiac patients with different clinical characteristics [7-11, 18]. Aetiology-related gene expression profiles have been identified in Chagas disease, and hypertrophic, dilated, viral and ischemic cardiomyopathies
Heidecker et al. identified a transcriptomic signature that could predict clinical outcome of new-onset idiopathic dilated cardiomyopathy patients [17]. Taken together, these findings offer valuable information regarding the molecular basis of HF related to distinct aetiologies and they could lead to individualized therapeutic strategies in HF.
Other clinical characteristics such as age and sex have also been shown to have an effect on the transcriptomal profile of HF patients [20] . In our study, the molecular severity markers correctly classified HF patients independent of aetiology or age. Because most of our patients were male, we could not validate our classification in female HF patients. We also showed that our results were unchanged when another prediction method was used [10, 17] . [24, 25] . [27, 28] . A previous report showed that a lower natriuretic peptide blood level, that usually implies a better outcome, may also imply poor outcome in severe HF patients [28] . Similarly [24] . Other HF severity prediction scores have been developed in advanced HF [3, 4] . Comparison of one of these HF severity predictors to the UNOS medical urgency status did not reveal a higher predictive power [4] . Other predictors included the measurement of peak oxygen consumption that cannot be recorded in the most severely affected patients [3] . 
Potential clinical significance of findings Prognosis evaluation for advanced HF patients
Our results showed that the LV and RV predictors lead to a better prediction of clinical status than the NPPB predictor, in particular regarding the prediction of the deteriorating status. It has previously been shown that the NPPB mRNA level in the LV and the BNP peripheral blood level are correlated [26]. The B-type natriuretic peptide (BNP) blood level is widely used as a clinical predictor for HF patients. However the BNP blood level predictive value is still controversial in the specific condition of end-stage HF
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